Imunon announces positive cmc meeting with fda for imnn-001 in treatment of advanced ovarian cancer

Company aligned with fda on cmc strategy and requirements in preparation of phase 3 pivotal trial of imnn-001 vertical integration of major components assures a high-quality, commercially viable future manufacturing capability on track to initiate phase 3 pivotal trial of imnn-001 in first quarter of 2025 lawrenceville, n.j., dec. 19, 2024 (globe newswire) -- imunon, inc. (nasdaq: imnn), a clinical-stage company in late-stage development with its dna-mediated immunotherapy, today announced the positive outcome of a type c chemistry, manufacturing, and controls (cmc) meeting with the u.s. food and drug administration (fda) regarding production of imnn-001 for the treatment of women with newly diagnosed advanced ovarian cancer.
CMC Ratings Summary
CMC Quant Ranking